The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)
Official Title: Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)
Study ID: NCT04402840
Brief Summary: The purpose of this study is to understand if it is safe and useful to perform SGB (Stellate Ganglion Block) in patients who have severe lung injury Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 infection.
Detailed Description: Primary Aim: ⢠To determine safety of stellate ganglion block (SGB) in ARDS Secondary Aim: * To determine efficacy of SGB in slowing the progression of ARDS
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
West Virginia University Rockefeller Neuroscience Institute, Morgantown, West Virginia, United States
Name: Ali R Rezai, MD
Affiliation: West Virginia University
Role: PRINCIPAL_INVESTIGATOR